cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2023-38-4-46-54cardiotomsk-2051Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЭндоваскулярная окклюзия ушка левого предсердия при фибрилляции предсердий: современные представления и перспективы (обзор)Endovascular occlusion of the left atrial appendage in atrial fibrillation: modern concepts and prospects (review)https://orcid.org/0000-0003-1510-9204КанорскийС. Г.KanorskiiS. G.

Sergey G. Kanorskii, Dr. Sci (Med), Professor, Head of the Department of Therapy No. 2, Faculty of Advanced Vocational Training and Retraining

4, Mitrofana Sedina str., Krasnodar, 350063

kanorskysg@mail.ruКубанский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияKuban State Medical University of Public Health Care of RussiaRussian Federation2023301220233844654Copyright © Канорский С.Г., 20232023Канорский С.Г.Kanorskii S.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/2051

Несмотря на все более широкое применение эндоваскулярной окклюзии ушка левого предсердия (ЭОУЛП) в практике лечения пациентов с фибрилляцией предсердий (ФП), выбор оптимальной тактики выполнения процедуры, особенно последующей антитромботической терапии, остается малоизученным. Настоящий обзор проведен с целью критической оценки современных представлений о безопасности и эффективности ЭОУЛП при ФП. Обсуждены результаты важнейших клинических исследований ЭОУЛП у пациентов с ФП, положения действующих клинических рекомендаций по проведению этой процедуры. Рассмотрены доступные данные о возможностях антитромботической терапии после ЭОУЛП, перспективы будущих исследований в устранении пробелов в доказательной базе данной методики.

Despite the increasingly widespread use of endovascular left atrial appendage occlusion (ELAAO) in the treatment of patients with atrial fibrillation (AF), the choice of optimal tactics for performing the procedure, especially subsequent antithrombotic therapy, remains poorly understood. This review was conducted with the aim of critically assessing current ideas about the safety and effectiveness of ELAAO in AF. The results of the most important clinical studies of ELAAO in patients with AF, the provisions of current clinical recommendations for this procedure are discussed. The available data on the possibilities of antithrombotic therapy after ELAAO and the prospects for future research in filling gaps in the evidence base for this technique are reviewed.

 

фибрилляция предсердийушко левого предсердияэндоваскулярная окклюзия ушка левого предсердияпероральная антикоагулянтная терапияантитромбоцитарная терапиятромбообразование на устройствеatrial fibrillationleft atrial appendageendovascular left atrial appendage closureoral anticoagulant therapyantiplatelet therapydevice-related thrombosisReferencesElliott A.D., Middeldorp M.E., Van Gelder I.C., Albert C.M., Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat. Rev. Cardiol. 2023;20(6):404–417. DOI: 10.1038/s41569-022-00820-8.Elliott A.D., Middeldorp M.E., Van Gelder I.C., Albert C.M., Sanders P. Epidemiology and modifiable risk factors for atrial fibrillation. Nat. Rev. Cardiol. 2023;20(6):404–417. DOI: 10.1038/s41569-022-00820-8.Escudero-Martínez I., Morales-Caba L., Segura T. Atrial fibrillation and stroke: A review and new insights. Trends Cardiovasc. Med. 2023;33(1):23–29. DOI: 10.1016/j.tcm.2021.12.001.Escudero-Martínez I., Morales-Caba L., Segura T. Atrial fibrillation and stroke: A review and new insights. Trends Cardiovasc. Med. 2023;33(1):23–29. DOI: 10.1016/j.tcm.2021.12.001.Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612.Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomström-Lundqvist C. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur. Heart J. 2021;42(5):373-498. DOI: 10.1093/eurheartj/ehaa612.Saw J., Holmes D.R., Cavalcante J.L., Freeman J.V., Goldsweig A.M., Kavinsky C.J. et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm. 2023;20(5):e1– e16. DOI: 10.1016/j.hrthm.2023.01.007.Saw J., Holmes D.R., Cavalcante J.L., Freeman J.V., Goldsweig A.M., Kavinsky C.J. et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm. 2023;20(5):e1– e16. DOI: 10.1016/j.hrthm.2023.01.007.Glikson M., Wolff R., Hindricks G., Mandrola J., Camm A.J., Lip G.Y.H. et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion an update. Europace. 2020;22(2):184. DOI: 10.1093/europace/euz258.Glikson M., Wolff R., Hindricks G., Mandrola J., Camm A.J., Lip G.Y.H. et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion an update. Europace. 2020;22(2):184. DOI: 10.1093/europace/euz258.January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C.Jr. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. DOI: 10.1161/CIR.0000000000000665.January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C.Jr. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ ACC/HRS Guideline for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. DOI: 10.1161/CIR.0000000000000665.Whitlock R.P., Belley-Cote E.P., Paparella D., Healey J.S., Brady K., Sharma M. et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N. Engl. J. Med. 2021;384(22):2081–2091. DOI: 10.1056/NEJMoa2101897.Whitlock R.P., Belley-Cote E.P., Paparella D., Healey J.S., Brady K., Sharma M. et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N. Engl. J. Med. 2021;384(22):2081–2091. DOI: 10.1056/NEJMoa2101897.Reddy V.Y., Sievert H., Halperin J., Doshi S.K., Buchbinder M., Neuzil P. et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. DOI: 10.1001/jama.2014.15192.Reddy V.Y., Sievert H., Halperin J., Doshi S.K., Buchbinder M., Neuzil P. et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988–1998. DOI: 10.1001/jama.2014.15192.Holmes D.R.Jr., Kar S., Price M.J., Whisenant B., Sievert H., Doshi S.K. et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol. 2014;64(1):1–12. DOI: 10.1016/j.jacc.2014.04.029.Holmes D.R.Jr., Kar S., Price M.J., Whisenant B., Sievert H., Doshi S.K. et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J. Am. Coll. Cardiol. 2014;64(1):1–12. DOI: 10.1016/j.jacc.2014.04.029.Reddy V.Y., Doshi S.K., Kar S., Gibson D.N., Price M.J., Huber K. et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J. Am. Coll. Cardiol. 2017;70(24):2964–2975. DOI: 10.1016/j.jacc.2017.10.021.Reddy V.Y., Doshi S.K., Kar S., Gibson D.N., Price M.J., Huber K. et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J. Am. Coll. Cardiol. 2017;70(24):2964–2975. DOI: 10.1016/j.jacc.2017.10.021.Boersma L.V., Ince H., Kische S., Pokushalov E., Schmitz T., Schmidt B. et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302–1308. DOI: 10.1016/j.hrthm.2017.05.038.Boersma L.V., Ince H., Kische S., Pokushalov E., Schmitz T., Schmidt B. et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302–1308. DOI: 10.1016/j.hrthm.2017.05.038.Berti S., Santoro G., Brscic E., Montorfano M., Vignali L., Danna P. et al. Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry. Int. J. Cardiol. 2017;248:103–107. DOI: 10.1016/j.ijcard.2017.07.052.Berti S., Santoro G., Brscic E., Montorfano M., Vignali L., Danna P. et al. Left atrial appendage closure using AMPLATZER™ devices: A large, multicenter, Italian registry. Int. J. Cardiol. 2017;248:103–107. DOI: 10.1016/j.ijcard.2017.07.052.Landmesser U., Tondo C., Camm J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590–e597. DOI: 10.4244/EIJ-D-18-00344.Landmesser U., Tondo C., Camm J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590–e597. DOI: 10.4244/EIJ-D-18-00344.Osmancik P., Herman D., Neuzil P., Hala P., Taborsky M., Kala P. et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J. Am. Coll. Cardiol. 2022;79(1):1–14. DOI: 10.1016/j.jacc.2021.10.023.Osmancik P., Herman D., Neuzil P., Hala P., Taborsky M., Kala P. et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J. Am. Coll. Cardiol. 2022;79(1):1–14. DOI: 10.1016/j.jacc.2021.10.023.Busu T., Khan S.U., Alhajji M., Alqahtani F., Holmes D.R., Alkhouli M. Observed versus expected ischemic and bleeding events following left atrial appendage occlusion. Am. J. Cardiol. 2020;125(11):1644–1650. DOI: 10.1016/j.amjcard.2020.02.041.Busu T., Khan S.U., Alhajji M., Alqahtani F., Holmes D.R., Alkhouli M. Observed versus expected ischemic and bleeding events following left atrial appendage occlusion. Am. J. Cardiol. 2020;125(11):1644–1650. DOI: 10.1016/j.amjcard.2020.02.041.Alkhouli M., Friedman P.A. ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week. J. Am. Coll. Cardiol. 2019;74(24):3050–3065. DOI: 10.1016/j.jacc.2019.10.040.Alkhouli M., Friedman P.A. ischemic stroke risk in patients with nonvalvular atrial fibrillation: JACC review topic of the week. J. Am. Coll. Cardiol. 2019;74(24):3050–3065. DOI: 10.1016/j.jacc.2019.10.040.Lakkireddy D., Thaler D., Ellis C.R., Swarup V., Sondergaard L., Carroll J. et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation. 2021;144(19):1543–1552. DOI: 10.1161/CIRCULATIONAHA.121.057063.Lakkireddy D., Thaler D., Ellis C.R., Swarup V., Sondergaard L., Carroll J. et al. Amplatzer Amulet left atrial appendage occluder versus Watchman device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation. 2021;144(19):1543–1552. DOI: 10.1161/CIRCULATIONAHA.121.057063.Dukkipati S.R., Kar S., Holmes D.R., Doshi S.K., Swarup V., Gibson D.N. et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874–885. DOI: 10.1161/CIRCULATIONAHA.118.035090.Dukkipati S.R., Kar S., Holmes D.R., Doshi S.K., Swarup V., Gibson D.N. et al. Device-related thrombus after left atrial appendage closure: incidence, predictors, and outcomes. Circulation. 2018;138(9):874–885. DOI: 10.1161/CIRCULATIONAHA.118.035090.Alkhouli M., Busu T., Shah K., Osman M., Alqahtani F., Raybuck B. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis. JACC Clin. Electrophysiol. 2018;4(12):1629–1637. DOI: 10.1016/j.jacep.2018.09.007.Alkhouli M., Busu T., Shah K., Osman M., Alqahtani F., Raybuck B. Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis. JACC Clin. Electrophysiol. 2018;4(12):1629–1637. DOI: 10.1016/j.jacep.2018.09.007.Kar S., Doshi S.K., Sadhu A., Horton R., Osorio J., Ellis C. et al. Primary Outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143(18):1754–1762. DOI: 10.1161/CIRCULATIONAHA.120.050117.Kar S., Doshi S.K., Sadhu A., Horton R., Osorio J., Ellis C. et al. Primary Outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX trial. Circulation. 2021;143(18):1754–1762. DOI: 10.1161/CIRCULATIONAHA.120.050117.Simard T., Jung R.G., Lehenbauer K., Piayda K., Pracoń R., Jackson G.G. et al. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J. Am. Coll. Cardiol. 2021;78(4):297–313. DOI: 10.1016/j.jacc.2021.04.098.Simard T., Jung R.G., Lehenbauer K., Piayda K., Pracoń R., Jackson G.G. et al. Predictors of device-related thrombus following percutaneous left atrial appendage occlusion. J. Am. Coll. Cardiol. 2021;78(4):297–313. DOI: 10.1016/j.jacc.2021.04.098.Sedaghat A., Vij V., Al-Kassou B., Gloekler S., Galea R., Fürholz M. et al. Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ. Cardiovasc. Interv. 2021;14(5):e010195. DOI: 10.1161/CIRCINTERVENTIONS.120.010195.Sedaghat A., Vij V., Al-Kassou B., Gloekler S., Galea R., Fürholz M. et al. Device-related thrombus after left atrial appendage closure: data on thrombus characteristics, treatment strategies, and clinical outcomes from the EUROC-DRT-Registry. Circ. Cardiovasc. Interv. 2021;14(5):e010195. DOI: 10.1161/CIRCINTERVENTIONS.120.010195.Simard T.J., Hibbert B., Alkhouli M.A., Abraham N.S., Holmes D.R.Jr. Device-related thrombus following left atrial appendage occlusion. EuroIntervention. 2022;18(3):224–232. DOI: 10.4244/EIJ-D-21-01010.Simard T.J., Hibbert B., Alkhouli M.A., Abraham N.S., Holmes D.R.Jr. Device-related thrombus following left atrial appendage occlusion. EuroIntervention. 2022;18(3):224–232. DOI: 10.4244/EIJ-D-21-01010.Asmarats L., Cruz-González I., Nombela-Franco L., Arzamendi D., Peral V., Nietlispach F. et al. recurrence of device-related thrombus after percutaneous left atrial appendage closure. Circulation. 2019;140(17):1441–1443. DOI: 10.1161/CIRCULATIONAHA.119.040860.Asmarats L., Cruz-González I., Nombela-Franco L., Arzamendi D., Peral V., Nietlispach F. et al. recurrence of device-related thrombus after percutaneous left atrial appendage closure. Circulation. 2019;140(17):1441–1443. DOI: 10.1161/CIRCULATIONAHA.119.040860.Tan B.E., Boppana L.K.T., Abdullah A.S., Chuprun D., Shah A., Rao M. et al. Safety and feasibility of same-day discharge after left atrial appendage closure with the WATCHMAN device. Circ. Cardiovasc. Interv. 2021;14(1):e009669. DOI: 10.1161/CIRCINTERVENTIONS.120.009669.Tan B.E., Boppana L.K.T., Abdullah A.S., Chuprun D., Shah A., Rao M. et al. Safety and feasibility of same-day discharge after left atrial appendage closure with the WATCHMAN device. Circ. Cardiovasc. Interv. 2021;14(1):e009669. DOI: 10.1161/CIRCINTERVENTIONS.120.009669.Saw J., Nielsen-Kudsk J.E., Bergmann M., Daniels M.J., Tzikas A., Reisman M. et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure. JACC Cardiovasc. Interv. 2019;12(11):1067–1076. DOI: 10.1016/j.jcin.2018.11.001.Saw J., Nielsen-Kudsk J.E., Bergmann M., Daniels M.J., Tzikas A., Reisman M. et al. Antithrombotic therapy and device-related thrombosis following endovascular left atrial appendage closure. JACC Cardiovasc. Interv. 2019;12(11):1067–1076. DOI: 10.1016/j.jcin.2018.11.001.Saliba W.I., Kawai K., Sato Y., Kopesky E., Cheng Q., Ghosh S.K.B. et al. Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device. JACC Clin. Electrophysiol. 2023;9(8Pt2):1555–1567. DOI: 10.1016/j.jacep.2023.04.013.Saliba W.I., Kawai K., Sato Y., Kopesky E., Cheng Q., Ghosh S.K.B. et al. Enhanced thromboresistance and endothelialization of a novel fluoropolymer-coated left atrial appendage closure device. JACC Clin. Electrophysiol. 2023;9(8Pt2):1555–1567. DOI: 10.1016/j.jacep.2023.04.013.Tan B.E., Wong P.Y., Lee J.Z., Tan N.Y., Rao M., Cheung J.W. Direct oral anticoagulant versus warfarin after left atrial appendage closure with WATCHMAN: updated systematic review and meta-analysis. Curr. Probl. Cardiol. 2022;47(11):101335. DOI: 10.1016/j.cpcardiol.2022.101335.Tan B.E., Wong P.Y., Lee J.Z., Tan N.Y., Rao M., Cheung J.W. Direct oral anticoagulant versus warfarin after left atrial appendage closure with WATCHMAN: updated systematic review and meta-analysis. Curr. Probl. Cardiol. 2022;47(11):101335. DOI: 10.1016/j.cpcardiol.2022.101335.Patti G., Pengo V., Marcucci R., Cirillo P., Renda G., Santilli F. et al. The left atrial appendage: from embryology to prevention of thromboembolism. Eur. Heart J. 2017;38(12):877–887. DOI: 10.1093/eurheartj/ehw159.Patti G., Pengo V., Marcucci R., Cirillo P., Renda G., Santilli F. et al. The left atrial appendage: from embryology to prevention of thromboembolism. Eur. Heart J. 2017;38(12):877–887. DOI: 10.1093/eurheartj/ehw159.Hildick-Smith D., Landmesser U., Camm A.J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Eur. Heart J. 2020;41(30):2894–2901. DOI: 10.1093/eurheartj/ehaa169.Hildick-Smith D., Landmesser U., Camm A.J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. Eur. Heart J. 2020;41(30):2894–2901. DOI: 10.1093/eurheartj/ehaa169.Landmesser U., Tondo C., Camm J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590–e597. DOI: 10.4244/EIJ-D-18-00344.Landmesser U., Tondo C., Camm J., Diener H.C., Paul V., Schmidt B. et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. EuroIntervention. 2018;14(5):e590–e597. DOI: 10.4244/EIJ-D-18-00344.Bergmann M.W., Ince H., Kische S., Schmitz T., Meincke F., Schmidt B. et al. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention. 2018;13(17):2003–2011. DOI: 10.4244/EIJ-D-17-00672.Bergmann M.W., Ince H., Kische S., Schmitz T., Meincke F., Schmidt B. et al. Real-world safety and efficacy of WATCHMAN LAA closure at one year in patients on dual antiplatelet therapy: results of the DAPT subgroup from the EWOLUTION all-comers study. EuroIntervention. 2018;13(17):2003–2011. DOI: 10.4244/EIJ-D-17-00672.Duthoit G., Silvain J., Marijon E., Ducrocq G., Lepillier A., Frere C. et al. Circ. Cardiovasc. Interv. 2020;13(7):e008481. DOI: 10.1161/CIRCINTERVENTIONS.119.008481.Duthoit G., Silvain J., Marijon E., Ducrocq G., Lepillier A., Frere C. et al. Circ. Cardiovasc. Interv. 2020;13(7):e008481. DOI: 10.1161/CIRCINTERVENTIONS.119.008481.Whitlock R.P., Belley-Cote E.P., Paparella D., Healey J.S., Brady K., Sharma M. et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N. Engl. J. Med. 2021;384(22):2081–2091. DOI: 10.1056/NEJMoa2101897.Whitlock R.P., Belley-Cote E.P., Paparella D., Healey J.S., Brady K., Sharma M. et al. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N. Engl. J. Med. 2021;384(22):2081–2091. DOI: 10.1056/NEJMoa2101897.Della Rocca D.G., Magnocavallo M., Di Biase L., Mohanty S., Trivedi C., Tarantino N. et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc. Interv. 2021;14(21):2353–2364. DOI: 10.1016/j.jcin.2021.07.031.Della Rocca D.G., Magnocavallo M., Di Biase L., Mohanty S., Trivedi C., Tarantino N. et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc. Interv. 2021;14(21):2353–2364. DOI: 10.1016/j.jcin.2021.07.031.Li X., Zhang X., Jin Q., Xue Y., Lu W., Ge J. et al. clinical efficacy and safety comparison of rivaroxaban and dabigatran for nonvalvular atri al fibrillation patients undergoing percutaneous left atrial appendage closure operation. Front. Pharmacol. 2021;12:614762. DOI: 10.3389/fphar.2021.614762.Li X., Zhang X., Jin Q., Xue Y., Lu W., Ge J. et al. clinical efficacy and safety comparison of rivaroxaban and dabigatran for nonvalvular atri al fibrillation patients undergoing percutaneous left atrial appendage closure operation. Front. Pharmacol. 2021;12:614762. DOI: 10.3389/fphar.2021.614762.Patti G., Sticchi A., Verolino G., Pasceri V., Vizzi V., Brscic E. et al. Safety and efficacy of single versus dual antiplatelet therapy after left atrial appendage occlusion. Am. J. Cardiol. 2020;134:83–90. DOI: 10.1016/j.amjcard.2020.08.013.Patti G., Sticchi A., Verolino G., Pasceri V., Vizzi V., Brscic E. et al. Safety and efficacy of single versus dual antiplatelet therapy after left atrial appendage occlusion. Am. J. Cardiol. 2020;134:83–90. DOI: 10.1016/j.amjcard.2020.08.013.Patti G., Ghiglieno C. Indications, evidence, and controversy in the closure of the left atrial appendage. Eur. Heart J. Suppl. 2023;25(Suppl. B):B126–B130. DOI: 10.1093/eurheartjsupp/suad091.Patti G., Ghiglieno C. Indications, evidence, and controversy in the closure of the left atrial appendage. Eur. Heart J. Suppl. 2023;25(Suppl. B):B126–B130. DOI: 10.1093/eurheartjsupp/suad091.Bing S., Chen R.R. Clinical efficacy and safety comparison of Watchman device versus ACP/Amulet device for percutaneous left atrial appendage closure in patients with nonvalvular atrial fibrillation: A study-level meta-analysis of clinical trials. Clin. Cardiol. 2023;46(2):117–125. DOI: 10.1002/clc.23956.Bing S., Chen R.R. Clinical efficacy and safety comparison of Watchman device versus ACP/Amulet device for percutaneous left atrial appendage closure in patients with nonvalvular atrial fibrillation: A study-level meta-analysis of clinical trials. Clin. Cardiol. 2023;46(2):117–125. DOI: 10.1002/clc.23956.Lakkireddy D., Thaler D., Ellis C.R., Swarup V., Gambhir A., Hermiller J. et al. 3-year outcomes from the amplatzer Amulet left atrial appendage occluder randomized controlled trial (Amulet IDE). JACC Cardiovasc Interv. 2023;16(15):1902–1913. DOI: 10.1016/j.jcin.2023.06.022.Lakkireddy D., Thaler D., Ellis C.R., Swarup V., Gambhir A., Hermiller J. et al. 3-year outcomes from the amplatzer Amulet left atrial appendage occluder randomized controlled trial (Amulet IDE). JACC Cardiovasc Interv. 2023;16(15):1902–1913. DOI: 10.1016/j.jcin.2023.06.022.

The authors declare that there are no conflicts of interest present.